| Code | Description | Claims | Beneficiaries | Total Paid |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
198,739 |
166,800 |
$29.53M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
120,049 |
105,972 |
$18.09M |
| 90834 |
Psychotherapy, 45 minutes with patient |
122,567 |
75,964 |
$14.03M |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
171,678 |
99,978 |
$11.70M |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
12,159 |
4,258 |
$7.53M |
| 71045 |
Radiologic examination, chest; single view |
49,995 |
41,586 |
$7.17M |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
107,253 |
82,882 |
$6.76M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
43,924 |
35,757 |
$5.96M |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
33,828 |
14,179 |
$4.92M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
12,763 |
10,289 |
$4.85M |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
91,779 |
74,487 |
$3.97M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
35,865 |
32,662 |
$3.88M |
| J9271 |
Injection, pembrolizumab, 1 mg |
664 |
373 |
$3.77M |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
70,656 |
17,588 |
$3.53M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
24,610 |
22,609 |
$3.16M |
| 96361 |
Intravenous infusion, hydration; each additional hour |
54,725 |
42,139 |
$2.18M |
| 90832 |
Psychotherapy, 30 minutes with patient |
15,922 |
12,571 |
$1.99M |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
26,019 |
23,170 |
$1.97M |
| Q3014 |
Telehealth originating site facility fee |
34,092 |
20,207 |
$1.76M |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
20,045 |
7,404 |
$1.73M |
| 70450 |
Computed tomography, head or brain; without contrast material |
14,101 |
11,486 |
$1.62M |
| 90791 |
Psychiatric diagnostic evaluation |
13,524 |
12,041 |
$1.48M |
| 71046 |
Radiologic examination, chest; 2 views |
15,300 |
12,981 |
$1.29M |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
33,001 |
23,277 |
$1.15M |
| 36591 |
|
21,034 |
9,157 |
$1.07M |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
231,379 |
167,921 |
$958K |
| 90837 |
Psychotherapy, 53 minutes with patient |
7,403 |
3,636 |
$916K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
58,897 |
38,204 |
$884K |
| 90839 |
|
7,260 |
6,237 |
$826K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
11,365 |
9,593 |
$804K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
12,166 |
10,339 |
$783K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
9,242 |
8,095 |
$687K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
3,534 |
3,305 |
$645K |
| J0897 |
Injection, denosumab, 1 mg |
546 |
396 |
$638K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
1,565 |
1,295 |
$589K |
| J1439 |
Injection, ferric carboxymaltose, 1 mg |
771 |
394 |
$577K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
107,491 |
85,220 |
$516K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
1,073 |
882 |
$479K |
| 84484 |
|
68,339 |
48,107 |
$472K |
| 90847 |
Family psychotherapy with the patient present, 50 minutes |
8,048 |
6,183 |
$467K |
| 80053 |
Comprehensive metabolic panel |
77,459 |
47,433 |
$387K |
| 36415 |
Collection of venous blood by venipuncture |
156,233 |
120,886 |
$372K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
2,187 |
725 |
$335K |
| 90792 |
Psychiatric diagnostic evaluation with medical services |
3,099 |
2,724 |
$316K |
| 96417 |
|
3,023 |
1,498 |
$304K |
| 81025 |
|
53,194 |
45,322 |
$293K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
4,039 |
2,992 |
$271K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
11,837 |
10,042 |
$255K |
| 77336 |
|
1,539 |
514 |
$206K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,218 |
1,120 |
$175K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
3,199 |
2,983 |
$164K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
2,478 |
1,581 |
$160K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
32,398 |
26,470 |
$151K |
| 83690 |
|
37,799 |
30,706 |
$130K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
3,231 |
2,968 |
$128K |
| 99217 |
|
363 |
246 |
$119K |
| 77386 |
|
134 |
13 |
$118K |
| 99218 |
|
334 |
228 |
$108K |
| 81001 |
|
54,514 |
44,685 |
$106K |
| 99221 |
|
273 |
199 |
$103K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
3,591 |
1,552 |
$101K |
| 80076 |
|
19,823 |
15,994 |
$100K |
| 99215 |
Prolong outpt/office vis |
773 |
707 |
$99K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
2,600 |
2,391 |
$95K |
| 99239 |
Hospital discharge day management, more than 30 minutes |
319 |
231 |
$95K |
| 87088 |
|
19,291 |
15,842 |
$90K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
767 |
682 |
$85K |
| 97161 |
|
793 |
681 |
$80K |
| 80047 |
|
17,108 |
13,651 |
$72K |
| 82728 |
|
9,691 |
7,717 |
$72K |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
47 |
37 |
$68K |
| J0185 |
Injection, aprepitant, 1 mg |
325 |
159 |
$67K |
| 80050 |
General health panel |
368 |
286 |
$63K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
1,666 |
1,436 |
$59K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
247 |
215 |
$55K |
| J0881 |
Injection, darbepoetin alfa, 1 microgram (non-esrd use) |
91 |
61 |
$53K |
| 77412 |
|
172 |
12 |
$50K |
| 77334 |
|
221 |
119 |
$44K |
| 83550 |
|
8,901 |
7,131 |
$43K |
| G0378 |
Hospital observation service, per hour |
730 |
265 |
$39K |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
31,850 |
12,475 |
$38K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
206 |
134 |
$36K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
2,994 |
2,242 |
$35K |
| 83540 |
|
8,926 |
7,150 |
$32K |
| 83880 |
|
1,624 |
1,253 |
$32K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
604 |
505 |
$32K |
| 90846 |
Family psychotherapy without the patient present, 50 minutes |
499 |
330 |
$31K |
| 93017 |
|
208 |
168 |
$30K |
| J1950 |
Injection, leuprolide acetate (for depot suspension), per 3.75 mg |
28 |
25 |
$28K |
| 76642 |
|
212 |
185 |
$25K |
| 96415 |
|
368 |
164 |
$24K |
| 95811 |
|
14 |
14 |
$23K |
| 99231 |
Subsequent hospital care, per day, straightforward or low complexity |
96 |
40 |
$22K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,037 |
865 |
$22K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
988 |
825 |
$21K |
| 87634 |
|
308 |
283 |
$18K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
43 |
40 |
$17K |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,718 |
1,436 |
$14K |
| 77300 |
|
77 |
62 |
$13K |
| 84439 |
|
3,385 |
1,868 |
$13K |
| 36592 |
|
615 |
343 |
$12K |
| 72170 |
|
447 |
360 |
$12K |
| 82607 |
|
1,382 |
1,050 |
$11K |
| 83520 |
|
780 |
591 |
$11K |
| 82746 |
|
1,253 |
945 |
$10K |
| 86334 |
|
1,156 |
798 |
$9K |
| 82784 |
|
856 |
632 |
$9K |
| 96416 |
|
48 |
25 |
$9K |
| 85014 |
|
6,930 |
5,509 |
$9K |
| 73564 |
|
241 |
107 |
$9K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
709 |
623 |
$7K |
| 99234 |
|
16 |
13 |
$7K |
| 97597 |
|
93 |
52 |
$7K |
| 20610 |
|
73 |
42 |
$7K |
| 82553 |
|
4,405 |
2,478 |
$7K |
| 72100 |
|
163 |
141 |
$7K |
| 96402 |
|
795 |
587 |
$6K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
151 |
126 |
$6K |
| 77065 |
Tomosynthesis, mammo |
45 |
38 |
$6K |
| 83735 |
|
1,737 |
725 |
$5K |
| 80305 |
|
467 |
362 |
$5K |
| 11045 |
|
29 |
12 |
$5K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
567 |
261 |
$5K |
| 85379 |
|
648 |
535 |
$4K |
| 96367 |
|
251 |
101 |
$4K |
| 84165 |
|
1,806 |
1,290 |
$4K |
| 74018 |
|
36 |
28 |
$4K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
23 |
13 |
$4K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
765 |
208 |
$3K |
| 81003 |
|
2,519 |
2,146 |
$3K |
| 77066 |
Tomosynthesis, mammo |
14 |
13 |
$3K |
| 71250 |
|
14 |
14 |
$3K |
| 76830 |
Ultrasound, transvaginal |
15 |
13 |
$3K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
15 |
15 |
$3K |
| 94799 |
|
185 |
79 |
$3K |
| 85027 |
|
809 |
593 |
$2K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
15 |
13 |
$2K |
| 84100 |
|
1,402 |
882 |
$2K |
| 83883 |
|
246 |
173 |
$2K |
| 87081 |
|
453 |
401 |
$2K |
| 87808 |
|
197 |
168 |
$2K |
| 82565 |
|
567 |
393 |
$2K |
| T1015 |
Clinic visit/encounter, all-inclusive |
78 |
76 |
$2K |
| 96376 |
|
697 |
416 |
$2K |
| 29581 |
|
21 |
12 |
$2K |
| J1756 |
Injection, iron sucrose, 1 mg |
30 |
12 |
$1K |
| 94760 |
|
44 |
12 |
$1K |
| J1631 |
Injection, haloperidol decanoate, per 50 mg |
281 |
194 |
$1K |
| 83521 |
|
108 |
57 |
$1K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
12 |
12 |
$1K |
| J9190 |
Injection, fluorouracil, 500 mg |
157 |
37 |
$1K |
| J2785 |
Injection, regadenoson, 0.1 mg |
29 |
27 |
$891.40 |
| 82947 |
|
161 |
72 |
$776.60 |
| 94060 |
|
13 |
12 |
$765.32 |
| 73562 |
|
20 |
16 |
$747.58 |
| 87905 |
|
80 |
66 |
$745.43 |
| 72125 |
Computed tomography, cervical spine; without contrast material |
15 |
12 |
$594.00 |
| 82657 |
|
62 |
54 |
$560.08 |
| 83921 |
|
78 |
56 |
$555.16 |
| 82077 |
|
45 |
42 |
$536.00 |
| 87077 |
|
110 |
88 |
$531.52 |
| 82962 |
|
241 |
107 |
$497.83 |
| 73610 |
|
19 |
13 |
$478.03 |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
232 |
162 |
$476.28 |
| 82378 |
|
52 |
39 |
$448.41 |
| 94761 |
|
37 |
13 |
$392.80 |
| 87641 |
|
12 |
12 |
$315.81 |
| 94726 |
|
13 |
12 |
$283.68 |
| 83605 |
|
36 |
27 |
$254.28 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
15 |
14 |
$244.89 |
| 83090 |
|
23 |
15 |
$207.88 |
| 84132 |
|
65 |
59 |
$190.96 |
| 80306 |
|
29 |
26 |
$185.30 |
| 81002 |
|
148 |
105 |
$176.26 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
9,586 |
7,444 |
$174.20 |
| 85610 |
|
49 |
38 |
$154.39 |
| 84295 |
|
51 |
47 |
$141.08 |
| 85018 |
|
158 |
87 |
$127.61 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
1,732 |
1,406 |
$123.86 |
| 84155 |
|
101 |
64 |
$113.10 |
| 82948 |
|
46 |
12 |
$84.98 |
| 84702 |
|
12 |
12 |
$83.56 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,727 |
632 |
$83.17 |
| 82435 |
|
30 |
27 |
$81.12 |
| 87186 |
|
16 |
13 |
$75.59 |
| 84520 |
|
30 |
27 |
$69.66 |
| 73130 |
|
46 |
39 |
$45.93 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
75 |
55 |
$37.28 |
| 83615 |
|
12 |
12 |
$26.04 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
14 |
12 |
$25.81 |
| 85378 |
|
15 |
12 |
$18.84 |
| J0401 |
Injection, aripiprazole (abilify maintena), 1 mg |
74 |
25 |
$4.97 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
5,139 |
3,894 |
$2.40 |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
292 |
238 |
$0.00 |
| J0640 |
Injection, leucovorin calcium, per 50 mg |
102 |
37 |
$0.00 |
| J2426 |
Injection, paliperidone palmitate extended release (invega sustenna), 1 mg |
132 |
44 |
$0.00 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
30 |
26 |
$0.00 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
302 |
203 |
$0.00 |
| J1750 |
Injection, iron dextran, 50 mg |
50 |
13 |
$0.00 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
120 |
37 |
$0.00 |
| 72110 |
|
17 |
12 |
$0.00 |
| 77387 |
|
164 |
12 |
$0.00 |
| J3370 |
Injection, vancomycin hcl, 500 mg |
36 |
25 |
$0.00 |
| 94729 |
|
13 |
12 |
$0.00 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
13 |
12 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
274 |
219 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
43 |
12 |
$0.00 |
| J2704 |
Injection, propofol, 10 mg |
44 |
26 |
$0.00 |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
14 |
14 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
15 |
13 |
$0.00 |